Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.
Zeng Z, Yang A, Yang J, Zhang S, Xing Z, Wang X, Mei W, Jiang C, Lin J, Wu X, Xue Y, Wu Z, Yu L, Wang D, Chen J, Zheng S, Lin Q, Chen Q, Dong J, Zheng X, Wang J, Huang J, Chen Z, Chen P, Zheng M, Zhou X, He Y, Lin Y, Chen J.
Zeng Z, et al.
Signal Transduct Target Ther. 2024 Sep 4;9(1):229. doi: 10.1038/s41392-024-01941-x.
Signal Transduct Target Ther. 2024.
PMID: 39227388
Free PMC article.
Clinical Trial.